According to a statement from White House press secretary Kayleigh McEnany, Trump received an 8-gram dose of the polyclonal antibody cocktail, REGN-COV2, from pharmaceutical company Regeneron, as a “precautionary measure.”
Polyclonal antibodies are made up of heterogeneous cells which “are usually produced by different B cell clones in the body,” according to Creative Diagnostics, a privately-owned American company specializing in the research and manufacturing of antibodies. Polyclonal antibodies can identify and attach to different epitomes, a specific piece of a single antigen.
They are produced in live beings, whereas monoclonal antibodies are produced using tissue-culture techniques, the biotechnology company reported.
To create the polyclonal antibodies, an immunogen is typically injected to elicit an immune response. An immunization is then injected to “produce higher titers of antibodies against the particular antigen.”
The experimental treatment uses an antibody made by the Regeneron, as well as with one isolated from people who have survived COVID-19. The intent is for the two antibodies to bind to the coronavirus’ protein, “limiting the ability of viruses to escape,” Reuters reported.
The treatment has shown effectiveness in decreasing the amount of virus in the body and severity of symptoms, Dr. Matt McCarthy, an infectious disease doctor, told FOX Business’s Stuart Varney.
“If I got brought in today to the Oval Office, first thing I’d say is, has anyone reached out to Regeneron?” McCarthy said. “Has anyone talked about an antibody cocktail for him? Three days ago, the company showed that they can reduce the amount of virus in the body and that they can decrease the duration of symptoms.”